Back to Search
Start Over
Emmaus Life Sciences revises Endari prescribing information
- Source :
- M2 Pharma. November 4, 2020
- Publication Year :
- 2020
-
Abstract
- M2 PHARMA-November 4, 2020-Emmaus Life Sciences revises Endari prescribing information (C)2020 M2 COMMUNICATIONS Emmaus Life Sciences Inc (OTC: EMMA), a company involved sickle cell disease treatment, has revised prescribing information [...]
- Subjects :
- Drug approval
Sickle cell anemia -- Drug therapy
Chemistry
Endari (Medication)
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 Pharma
- Publication Type :
- News
- Accession number :
- edsgcl.640502667